Open Access Research
Impact of the pretransplant dialysis
modality on kidney transplantation
outcomes: a nationwide cohort study
Huan-Tang Lin,1,2 Fu-Chao Liu,1,2 Jr-Rung Lin,1,2,3 See-Tong Pang,2,4
Huang-Ping Yu1,2,5
To cite: Lin H-T, Liu F-C, AbstrACt
strengths and limitations of this study
Lin J-R, et al. Impact of the Objective Most patients with uraemia must undergo
pretransplant dialysis modality chronic dialysis while awaiting kidney transplantation;
on kidney transplantation ► This is the first nationwide population-based cohort
however, the role of the pretransplant dialysis modality on
outcomes: a nationwide study to demonstrate that pretransplant haemodi-
the outcomes of kidney transplantation remains obscure.
cohort study. BMJ Open alysis contributed to higher risks of allograft failure
The objective of this study was to clarify the associations
2018;8:e020558. doi:10.1136/ after kidney transplantation when compared with
bmjopen-2017-020558 between the pretransplant dialysis modality, namely peritoneal dialysis.
haemodialysis (HD) or peritoneal dialysis (PD), and the
► Prepublication history for development of post-transplant de novo diseases, allograft ► The nationwide database covers more than 99% of
this paper is available online. the Taiwanese population.
failure and all-cause mortality for kidney-transplant
To view these files, please visit ► Our study had a relatively large number of recipients
recipients.
the journal online (http://d x. doi. and a long follow-up duration compared with other
Design Retrospective nationwide cohort study.
org/ 10. 1136/ bmjopen- 2017- studies.
020558). setting Data retrieved from the Taiwan National Health ► Because of the lack of clinical data on graft function
Insurance Research Database.
and laboratory results, we could not determine the
H-TL and F-CL contributed Participants The National Health Insurance database was
mechanism of graft failure.
equally. explored for patients who received kidney transplantation
in Taiwan during 1998–2011 and underwent dialysis >90
Received 9 November 2017
days before transplantation.
Revised 29 March 2018
Accepted 11 May 2018 Outcome measures The pretransplant characteristics, renal disease (ESRD), offering substantial
complications during kidney transplantation and post- benefits in terms of healthcare costs, life
transplant outcomes were statistically analysed and expectancy and quality of life.1 2 However,
compared between the HD and PD groups. Cox regression
kidney transplantation is often not accessible
analysis was used to evaluate the HR of the dialysis
due to organ shortage, and most patients
modality on graft failure and all-cause mortality. The
with ESRD must undergo renal replacement
primary outcomes were long-term post-transplant death-
therapy such as haemodialysis (HD) or peri-
censored allograft failure and all-cause mortality started
toneal dialysis (PD) while awaiting a donor
after 90 days of kidney transplantation until the end of
follow-up. The secondary outcomes were events during kidney. HD is the most commonly used dial-
kidney transplantation and post-transplant de novo diseases ysis modality worldwide, with at least 80% of
adjusted by propensity score in log-binomial model. chronic dialysis patients receiving in-centre
1Department of Anesthesiology,
results There were 1812 patients included in our HD in three-fourths of reporting countries in
Chang Gung Memorial Hospital,
Taoyuan, Taiwan cohort, among which 1209 (66.7%) and 603 (33.3%) 2014.3 Meanwhile, PD seems to be underused
2College of Medicine, Chang recipients received pretransplant HD and PD, respectively. in most countries; in 2014, only 9.5% of dial-
Gung University, Taoyuan, Recipients with chronic HD were generally older and male, ysis patients used this modality in the USA.1 4 5
Taiwan had higher risks of developing post-transplant de novo
The estimated life expectancy of patients with
3Clinical Informatics and ischaemic heart disease, tuberculosis and hepatitis C after
ESRD receiving HD or PD are nearly equal
Medical Statistics Research adjustment. Pretransplant HD contributed to higher graft
Center, Graduate Institute of failure in the multivariate analysis (HR 1.38, p<0.05) after (19.11 vs 19.08 years). However, PD is more
Clinical Medicine, Chang Gung cost-effective than HD after considering the
adjustment for the recipient age, sex, duration of dialysis
University, Taoyuan, Taiwan quality of life, dialysis costs and its associ-
and pretransplant diseases. There was no significant
4Department of Urology, Chang between-group difference in overall survival. ated complications.6 Thus, the promotion of
Gung Memorial Hospital,
Taoyuan, Taiwan Conclusions Pretransplant HD contributed to higher a PD-first policy has modestly increased the
5Department of Anesthesiology, risks of death-censored allograft failure after kidney overall trends of PD use in chronic dialysis
Xiamen Changgung Hospital, transplantation when compared with PD. patients in the USA and other countries since
Taoyuan, Taiwan 2006.7
IntrODuCtIOn Although the short-term outcomes of kidney
Correspondence to
Dr Huang-Ping Yu; Kidney transplantation is the preferable and transplantation have significantly improved
yuhp2001@ adm. cgmh. org. tw definite therapy for patients with end-stage over the past three decades, owing to modern
Lin H-T, et al. BMJ Open 2018;8:e020558. doi:10.1136/bmjopen-2017-020558 1
Open Access
medical care and immunosuppression, the long-term graft The present study conformed to the Declaration of
survival has shown minimal improvement.8 This discrep- Helsinki of 1975, as revised in 2000. As the data used in
ancy is often attributed to the increasing use of expand- this study were anonymised, the need for patient consent
ed-criteria donor kidneys, the ageing of the recipient was waived.
population, alloantibody-mediated graft injury and recur-
rent glomerular pathologies.9 10 The long-term outcomes Patient selection
of kidney transplantation are determined by factors The eligible population comprised 23 462 863 benefi-
relating to the donor, graft function, recipient and immu- ciaries registered in the NHI database in 2013. The total
nosuppression.8 Among these intricate characteristics, the studied NHI database spanned from 1997 to 2013, but to
dialysis modality seems to be the most readily modifiable ensure data integrity and adequate follow-up periods, we
factor. Previous studies have reported inconsistent results included kidney recipients in Taiwan between 1998 and
regarding the effect of the pretransplant dialysis modality on 2011 for further analysis. We identified patients receiving
the outcomes of kidney transplantation. A cohort study of kidney transplantation in Taiwan in the NHI databases
simultaneous pancreas-kidney transplantation for patients using the ICD-9 diagnosis code of kidney transplant status
with type 1 diabetes showed an association between the use (V42.0) and operation codes of kidney transplantation
of PD and worse outcomes secondary to increased inci- (55.6, 76020A, 76020B and 97416K). In order to examine
dences of graft thrombosis, new-onset diabetes after trans- long-term post-transplant outcomes between patients
plantation and intra-abdominal infection, thus leading receiving pretransplant chronic HD and PD, we excluded
to worse patient survival.11 In contrast, other studies have patients who did not meet with our requirements such as
found better kidney transplantation outcomes in patients dialysis less than 90 days, unconfirmed dialysis modality
receiving PD, including lower incidences of delayed graft and uncertain dialysis duration.
function (DGF), shorter pretransplant dialysis duration
and better long-term patient survival.12 13 These conflicting measurements
results might originate from factors other than the dialysis The clinicodemographic characteristics of the kidney-trans-
modality, such as different donor characteristics, follow-up plant recipients with HD or PD were identified and compared,
durations and the methodological design of these studies including their age, sex, residence area, income level, dial-
(ie, registry-based or single-centre studies).14 ysis duration, Charlson Comorbidity Index (CCI) score,
Taiwan had the highest prevalence and incidence pretransplant diseases, events during kidney transplantation,
of ESRD and dialysis in the world since 2000,3 but post-transplant de novo diseases and kidney transplantation
convincing evidence-based studies regarding suggested outcomes. Only patients with the preoperative disease codes
dialysis modality for patients with ESRD awaiting kidney identified in the NHI database between 1998 and 2011 at
transplantation were scarce, especially in Asian popula- least once in the inpatient setting or >3 times in outpatient
tion. Therefore, we conducted this nationwide cohort visits were included. The CCI score, which comprises 17
study based on the National Health Insurance (NHI) diagnostic criteria, was used to evaluate the patients’ medical
database of Taiwan to compare the clinicodemographic burden before kidney transplantation. The analysed disease
characteristics, post-transplant de novo diseases and with accompanied ICD-9 code for between-group compar-
kidney transplantation outcomes between the different ison were as follows: hypertension (401–405), diabetes
dialysis modalities. (250), ischaemic heart disease (410–414), heart failure
(428), stroke (430–438), liver cirrhosis (571–572), malig-
nancy (140–208) and hepatitis C (070.4). The recorded
PAtIents AnD methODs events with accompanied ICD-9 code during hospitalisa-
Data collection tion for kidney transplantation were dialysis events, vascular
We conducted a retrospective nationwide cohort study thrombosis (444, 453), and infection episodes (including
based on Taiwan’s NHI database. This database routinely bacteraemia (790.7), peritonitis (567), pneumonia (480–
collects health information from all NHI beneficiaries in 486) and urinary tract infection (UTI) (599.0)). Post-trans-
Taiwan since 1995. The NHI is a single medical expense plant de novo diseases were defined as new-onset diseases
payer system that covered over 99.6% of registered bene- recorded during our follow-up period started after 90 days of
ficiaries in the NHI database at the end of 2014. Deidenti- kidney transplantation until the end of follow-up or patient
fied and computerised data were provided by the Bureau death. The analysed de novo diseases include hypertension,
of NHI, which organises claimed data for the entire NHI ischaemic heart disease, peripheral arterial occlusive disease
system and has established the NHI research database. (440), psychiatric disease (300, 301), tuberculosis (010–
Basic patient information and medical data are encrypted 018), malignancy, chronic obstructive pulmonary disease
and encoded using the International Classification of (490–496), liver cirrhosis, herpes zoster (053), hepatitis B
Diseases, Ninth Revision, Clinical Modification (ICD-9) (070.3) and hepatitis C.
codes in our included NHI database during 1997–2013.
The validity, representativeness and clinical consistency Patients and public involvement
of this database have been reported in many previous No patients or public were involved in setting out the
studies.15 research question or developing the outcome measures,
2 Lin H-T, et al. BMJ Open 2018;8:e020558. doi:10.1136/bmjopen-2017-020558
Open Access
nor were they involved in developing plans for design or results
implementation of the study. No patients or public were Clinical characteristics of kidney-transplant recipients with
asked to advise on interpretation or writing up of results, different dialysis modalities
nor was the burden of the interventions on patients Figure 1 shows a flow chart of the patient selection and
assessed. The results of the research will be disseminated identification programme in our study. There were 2741
to those study participants who wished to be notified of patients receiving kidney transplantation in Taiwan
them. between 1998 and 2011. Then we excluded 359 patients
who did not receive chronic dialysis before kidney trans-
plantation (dialysis <90 days or <5 times), and 126 patients
statistical analysis who had a non-specific dialysis modality (concomitant use
The primary outcomes in our study were long-term or transition from one to the other). To ensure accurate
post-transplant allograft failure and all-cause mortality estimation of the dialysis duration, we also excluded 420
during our follow-up period started after 90 days of patients who had dialysis records before 31 March 1997.
kidney transplantation until the end of follow-up. We Finally, since the primary outcome of allograft failure in
defined allograft failure as return to chronic dialysis our study was defined as re-entry of chronic dialysis >90
(>90 days) after kidney transplantation or as receiving days after kidney transplantation or retransplantation, we
another kidney transplantation. Because allograft failure excluded 24 patients from our cohort because they died
and death act as competing events after kidney trans- within 90 days of kidney transplantation (17 and 7 patients
plantation, we applied the concept of competing-risk in the HD and PD groups, respectively) thus hampered
framework and used death-censored allograft failure as the observation. The final cohort consisted of 1812 recip-
our measured outcome in the Cox proportional hazard ients of kidney transplantation during 1998–2011, among
model.16 17 On the other hand, since the true cause of which 1209 (67%) and 603 (33%) patients had undergone
death was unavailable in our NHI database, all-cause pretransplant chronic HD and PD, respectively. Table 1
mortality was chose as another primary outcome and lists the comparison of clinical characteristics between
was defined as detection of death codes or termination kidney-transplant recipients with chronic HD and with
of NHI. Because recipients with pretransplant HD or chronic PD. The median(Q1–Q3) follow-up duration was
PD had different characteristics, significant pretrans- 6.06 (3.84–8.92) years, and follow-up durations were similar
in both groups. Patients with chronic HD were older
plant recipient factors (including recipient sex, age,
(44.79±11.57 vs 38.28±13.45 years) and more frequently
dialysis duration and pretransplant diseases (diabetes,
male. Analysis of the age distribution showed that more
stroke and heart failure)) were selected to adjust
young patients (<18 years) in the PD group and more old
death-censored graft failure and all-cause mortality in
patients (>65 years) in the HD group. There was no obvious
multivariate analyses. Subsequently, survival curves of
difference in the geographical distribution between the
pretransplant dialysis modality on kidney transplanta-
different dialysis groups, except significantly more recipi-
tion outcomes based on the Cox proportional hazard
ents in southern Taiwan choosing HD. There were more
model were plotted and the between-group differences
recipients with a low-income level choosing PD (quintiles 1
were compared.
and 2: 57.04% in PD vs 54.68% in HD). Recipients with HD
The secondary outcomes were events during kidney
had higher CCI scores (2.54±0.87 in HD vs 2.38±0.63 in PD,
transplantation and post-transplant de novo diseases
p<0.05) and longer pretransplant dialysis durations (3.33
during follow-up period started after 90 days of kidney
(1.58–5.64) years in HD vs 2.67 (1.32–4.33) years in PD,
transplantation until the end of follow-up or patient
p<0.05). Regarding the pretransplant comorbidities in the
death. Because different characteristics between recip-
different dialysis modality groups, recipients with HD had
ients with pretransplant HD and pretransplant PD,
significant higher incidences of diabetes, ischaemic heart
we applied propensity score covariate adjustment in
disease, heart failure, stroke and hepatitis C. As for our
log-binomial regression model to calculate relative risks
primary outcomes, the cumulative incidences of allograft
(RR) for the secondary outcomes.18 19 The propensity
failure during 1998–2011 were significantly higher in recip-
score covariates used for adjustment were selected from
ients with HD compared with the PD group (15.63% in HD
significant pretransplant factors and were the same
vs 11.44% in PD, p<0.05), whereas there was no significant
as these used in multivariate analyses (ie, recipient
difference in cumulative incidences of all-cause mortality
sex, age, dialysis duration and pretransplant diseases (11.41% in HD vs 8.96% in PD, p=0.109).
(diabetes, stroke and heart failure)). Sensitivity analysis
of the propensity score model was assessed by calcu- Adverse events during hospitalisation for kidney
lating the c-statistic, which showed good discrimination transplantation
in adjusting potential confounding associated with the Table 2 shows the impact of the different dialysis modalities
choice of dialysis modality.20 on the events during hospitalisation for kidney transplan-
All statistical analyses were conducted using SAS soft- tation after propensity score adjustment. Recipients with
ware (V.9.4; SAS Institute), with p<0.05 considered statis- chronic PD had significantly higher infection risks in perito-
tically significant. nitis (RR of HD over PD 0.15, 95% CI 0.04 to 0.58, p<0.05)
Lin H-T, et al. BMJ Open 2018;8:e020558. doi:10.1136/bmjopen-2017-020558 3
Open Access
Figure 1 Study design and flow chart of the patient selection. NHI, National Health Insurance.
and UTI (RR of HD over PD 0.66, 95% CI 0.45 to 0.96, Post-transplant outcomes of kidney transplantation in
p<0.05) compared with patients with HD. Regarding the different dialysis modalities
risks of vascular thrombosis, there was no significant differ- The post-transplant outcomes (ie, death-censored graft
ences after propensity score adjustment. On the contrary, failure and all-cause mortality) were compared between
recipients with HD experienced more dialysis events during the HD and PD groups using Cox proportional hazard
kidney transplantation after adjustment (1.59 in HD vs 0.71 analysis (table 4), then significant pretransplant factors
in PD, p<0.05). There was no significant between-group (recipient age, sex, dialysis duration and pretrans-
difference in hospitalisation duration for kidney transplan- plant diseases (diabetes, stroke and heart failure))
tation after adjustment (18.19 days in HD vs 18.15 days in were adjusted in the multivariate analyses. The HR of
PD, p=0.951). death-censored graft failure between different dialysis
modalities was not significant in univariate analysis,
new-onset diseases during follow-up period after 90 days of but became significant (HR 1.38, 95% CI 1.03 to 1.84,
kidney transplantation p<0.05) after adjustment. This result implied that great
As seen in table 3, compared with patients with PD, recip- differences existed in recipients with different dialysis
ients with chronic HD had significantly higher risks of modalities, and we had to eliminate these confounding
developing post-transplant de novo diseases after propen- factors before comparison to clarify our result, that is,
sity score adjustment including ischaemic heart disease pretransplant HD contributed to significantly higher
(RR 2.40, 95% CI 1.21 to 4.77, p<0.05), tuberculosis (RR risks of allograft failure among surviving recipients. The
10.23, 95% CI 1.35 to 77.47, p<0.05) and hepatitis C (RR death-censored graft survival curve between different
2.66, 95% CI 1.33 to 5.35, p<0.05). dialysis modalities was showed in figure 2, which revealed
4 Lin H-T, et al. BMJ Open 2018;8:e020558. doi:10.1136/bmjopen-2017-020558
Open Access
Table 1 Clinical characteristics of kidney-transplant recipients with different dialysis modalities during 1998–2011
All (n=1812) HD (n=1209) PD (n=603) P values
Age, year (mean±SD) 42.62±12.60 44.79±11.57 38.28±13.45 <0.001*
Sex, no (%) 0.056
Male 679 (56.16) 310 (51.41)
Female 530 (43.84) 293 (48.59)
Resident area, no (%)
North 605 (50.12) 314 (52.16) 0.415
Central 191 (15.82) 114 (18.94) 0.096
South 372 (30.82) 154 (25.58) 0.021*
East 35 (2.90) 18 (2.99) 0.915
other 4 (0.33) 2 (0.33) 1.000
Income level, no (%)
Quintile 1 249 (20.60) 184 (30.51) <0.001*
Quintile 2 412 (34.08) 160 (26.53) 0.001*
Quintile 3 131 (10.84) 54 (8.96) 0.213
Quintile 4 198 (16.38) 80 (13.27) 0.083
Quintile 5 219 (18.11) 125 (20.73) 0.181
Pretransplant dialysis duration, year, median (Q1–Q3) 3.33 (1.58–5.64) 2.67 (1.32–4.33) <0.001*
Pretransplant CCI score, mean±SD 2.54±0.87 2.38±0.63 <0.001*
Pretransplant disease, no (%)
Hypertension 919 (76.01) 497 (82.47) 0.002
Diabetes 222 (18.36) 52 (8.62) <0.001*
Ischaemic heart disease 216 (17.87) 64 (10.61) <0.001*
Heart failure 147 (12.16) 34 (5.64) <0.001*
Stroke 77 (6.37) 17 (2.82) 0.001*
Liver cirrhosis 15 (1.24) 4 (0.66) 0.332
Malignancy 35 (2.89) 14 (2.32) 0.478
Hepatitis C 84 (6.95) 12 (1.99) <0.001*
Graft failure, no (%) 258 (14.24) 189 (15.63) 69 (11.44) 0.016*
Re-entry of chronic dialysis 172 (14.23) 63 (10.45) 0.024*
Retransplantation 17 (1.41) 6 (1) 0.461
Time to failure, year, median (Q1–Q3) 3.22 (0.27–5.58) 2.30 (0.41–4.13) 0.018*
Patient death, no (%) 192 (10.60) 138 (11.41) 54 (8.96) 0.109
Time to death, year, median (Q1–Q3) 2.79 (0.82–6.31) 1.15 (0.62–4.16) 0.014*
Hospitalisation duration†, day (mean) 18.19 18.15 0.951
Dialysis events†, no (mean) 1.59 0.71 <0.001*
*P<0.05.
†The hospitalisation duration and dialysis events during kidney transplantation have been propensity adjusted in log-binomial model by
factors including recipient age, sex and pretransplant diseases (diabetes, stroke and heart failure).
CCI, Charlson Comorbidity Index; HD, haemodialysis; PD, peritoneal dialysis.
that the graft survival probability was significantly higher DIsCussIOn
in PD than HD group (p=0.031) after 10 years of kidney In this nationwide cohort study using the NHI database
transplantation during the whole follow-up period. of Taiwan during 1998–2011, we found that kidney-trans-
On the other hand, there was no significant difference plant recipients with chronic HD had significantly
regarding all-cause mortality between the HD and PD higher incidences of pretransplant cardiovascular
groups either in the Cox regression analysis (table 4) or diseases; higher risks of developing post-transplant de
in survival curve (figure 3). novo ischaemic heart disease, tuberculosis and hepatitis
Lin H-T, et al. BMJ Open 2018;8:e020558. doi:10.1136/bmjopen-2017-020558 5
Open Access
transplantation, recipients with PD had higher risks of
Table 2 Events during hospitalisation for kidney
developing infection such as peritonitis and UTI, while
transplantation between different dialysis modalities after
recipients with HD were associated with more dialysis
propensity score adjustment†
events and, theoretically, a higher risk of DGF. Moreover,
Events
our results indicated that pretransplant HD conferred
during kidney RR‡ (HD vs
transplantation PD) 95% CI P values significantly worse long-term allograft survival after
kidney transplantation, possibly explained by the higher
Infection episodes, 0.68 (0.48 to 0.95) 0.022*
cardiovascular risk and impaired immunity in recipi-
no
ents with chronic HD. Therefore, PD might be a better
Bacteraemia 1.81 (0.17 to 18.94) 0.619
pretransplant dialysis modality than HD for patients with
Peritonitis 0.15 (0.04 to 0.58) 0.006*
ESRD awaiting kidney transplantation in Taiwan in terms
Pneumonia 1.38 (0.48 to 3.94) 0.547 of cost-effectiveness and long-term allograft survival.
Urinary tract 0.66 (0.45 to 0.96) 0.029* Taiwan has been recognised as an epidemic area of
infection kidney disease, and the corresponding health expendi-
Vascular 2.76 (0.32 to 23.56) 0.354 ture comprised up to 6% of total health insurance budget
thrombosis for caring 0.3% of Taiwanese population receiving dial-
ysis.21 The underlying reasons behind the extraordinarily
*P<0.05.
†The propensity scores for adjustment included recipient sex, high incidence and prevalence of uraemia and dialysis
age, dialysis duration and pretransplant diseases (diabetes, in Taiwan have often been attributed to global coverage
stroke and heart failure). of the dialysis costs for every citizen since 1995, without
‡RR was expressed as HD as dialysis modality compared with
copayment, in the NHI system; the relatively low mortality
PD.
rates in patients with uraemia; and the relatively low
HD, haemodialysis; PD, peritoneal dialysis; RR, relative risk.
kidney transplantation rate in Taiwan.22 Although PD is
C after propensity score adjustment; and higher HR of used in only 9.2% of dialysis patients in Taiwan,3 one-third
death-censored allograft failure in the multivariate anal- of kidney-transplant recipients received pretransplant PD
ysis compared with their PD counterpart. The between- in our cohort, which might be the result of the younger
group difference in post-transplant all-cause mortality was age distribution and better preserved renal function in
insignificant in the Cox regression analysis. During kidney patients with PD.23 24 Our results also showed that recipi-
ents with chronic HD had significantly higher incidences
Table 3 New-onset diseases after 90 days of kidney of pretransplant diabetes, cardiovascular diseases and
transplantation during follow-up period after propensity
hepatitis C, and a higher CCI score, which might originate
score adjustment†
from the pronounced vascular calcification and impaired
New-onset RR§ (HD vs cellular immunity in patients with chronic HD.25 26
disease‡ PD) 95% CI P values
The United Network for Organ Sharing defined DGF
Hypertension 1.23 (0.85 to 1.80) 0.275 as the need for at least one dialysis within the first week
Ischaemic heart 2.40 (1.21 to 4.77) 0.013* of kidney transplantation, which is commonly attributed
disease to ischaemia and reperfusion injury.27 DGF is associated
PAOD 1.11 (0.38 to 3.24) 0.843 with increased risk of chronic allograft nephropathy and
Psychiatric 1.46 (0.87 to 2.46) 0.152 shortened allograft survival.28 Although DGF could not
disease be directly identified in our NHI database, there were
Tuberculosis 10.23 (1.35 to 77.47) 0.024* significantly more dialysis events in HD patients during
Malignancy 1.03 (0.67 to 1.57) 0.897 hospitalisation for kidney transplantation. Therefore, it
is reasonable to deduce that recipients with HD are more
COPD 1.15 (0.51 to 2.60) 0.735
likely to have DGF, thus leading to worse allograft survival.
Liver cirrhosis 2.12 (0.77 to 5.81) 0.143
This finding is consistent with previous studies reporting
Herpes zoster 1.09 (0.91 to 1.31) 0.358
that kidney recipients with chronic PD had fewer DGF
Hepatitis B 0.94 (0.58 to 1.54) 0.821
events, better recovery of renal function and improved
Hepatitis C 2.66 (1.33 to 5.35) 0.006* graft survival comparing to recipients with HD.29 These
observations might be ascribed to the fluid expansion
*P<0.05.
†The propensity scores for adjustment included recipient sex, age, status and better preserved residual renal function in
dialysis duration and pretransplant diseases (diabetes, stroke and chronic PD patients.22
heart failure).
On the other hand, recipients with pretransplant PD
‡New-onset disease was defined as a specific disease code
had higher risks of developing peritonitis and UTI during
presented in the NHI database during follow-up period started
after 90 days of kidney transplantation until the end of follow-up hospitalisation for kidney transplantation. Previous studies
without a prior history of that disease. have shown that PD patients are more frequently compli-
§RR was expressed as HD as dialysis modality compared with PD.
cated with intra-abdominal infection during kidney trans-
COPD, chronic obstructive pulmonary disease; HD, haemodialysis;
plantation, leading to higher risks of early graft failure
NHI, National Health Insurance; PAOD, peripheral arterial occlusive
disease; PD, peritoneal dialysis; RR, relative risk. and worse overall survival.11 However, the incidence of
6 Lin H-T, et al. BMJ Open 2018;8:e020558. doi:10.1136/bmjopen-2017-020558
Open Access
Table 4 Cox proportional hazard analyses of death-censored graft failure and all-cause mortality after kidney transplantation
Univariate analysis Multivariate analysis†
Variables HR (95% CI) P values HR (95% CI) P values
Death-censored graft failure
HD as dialysis modality (vs PD) 1.29 (0.98 to 1.71) 0.066 1.38 (1.03 to 1.84) 0.031*
All-cause mortality
HD as dialysis modality (vs PD) 1.19 (0.87 to 1.63) 0.285 0.85 (0.61 to 1.18) 0.333
*P<0.05.
†Adjusted for recipient sex, age, dialysis duration and pretransplant diseases (diabetes, stroke and heart failure).
HD, haemodialysis; PD, peritoneal dialysis.
acute rejection after kidney transplantation is similar in in patients receiving HD.25 Although successful kidney
recipients with PD or with HD under modern immuno- transplantation might reduce cardiovascular risks, cardio-
suppression.30 Combining these adverse events during vascular disease remains the leading cause of graft failure
kidney transplantation, recipients with HD might be at a and mortality for patients with a functioning graft.31
higher risk of developing DGF after kidney transplanta- Further, chronic HD is associated with impaired cellular
tion, leading to worse graft survival, while recipients with immunity, mainly due to a deficiency in the interaction of
PD might have more controllable infection risks. T-cells with the antigen-presenting cells24; this might be
Our analysis showed that recipients with HD had higher responsible for the higher incidences of tuberculosis and
risks of developing de novo ischaemic heart disease, hepatitis C in recipients with HD in our results. Impaired
tuberculosis and hepatitis C after kidney transplantation. immunity in HD patients could exacerbate chance infec-
Vascular calcification, which mainly results from alter- tions, such as tuberculosis, hepatitis C, cytomegalovirus
ations of mineral and bone metabolism during chronic and BK polyomavirus reactivation after transplantation,
dialysis, is the major cause of enhanced cardiovascular thus imposing serious threats of allograft loss and patient
risk in patients with uraemia and is more pronounced death.32–34
Figure 2 Survival curves of the adjusted Cox proportional hazard model for death-censored graft survival according to the
different dialysis modalities. (A) Recipients with peritoneal dialysis had significantly higher death-censored graft survival than
recipients with haemodialysis after 10 years of kidney transplantation (p=0.031). (B) The whole follow-up period was 14 years
(from 1998 to 2011).
Lin H-T, et al. BMJ Open 2018;8:e020558. doi:10.1136/bmjopen-2017-020558 7
Open Access
Figure 3 Survival curves of the adjusted Cox proportional hazard model for overall survival according to the different dialysis
modalities. (A) There were no significant differences in post-transplant patient survival between recipients with peritoneal
dialysis and recipients with haemodialysis (p=0.333). (B)The whole follow-up period was 14 years (from 1998 to 2011).
The reported recipient factors affecting the long-term together of these studies, we might be able to summarise
outcomes of kidney transplantation include the recip- that pretransplant HD confer worse long-term outcomes
ient age, sex, human leukocyte antigen (HLA) matching, after kidney transplantation, which might be ascribed
dialysis duration, cardiovascular comorbidities and dial- to impaired immunity and higher cardiovascular risks
ysis modality.8 35 Increasing dialysis exposure is asso- in chronic HD patients. However, the influence of the
ciated with higher risks for developing cross-reactive dialysis modality on the kidney transplantation outcomes
antidonor T-cell immunity and cardiovascular diseases, might be only modest, especially under modern sophisti-
thus leading to worse long-term outcomes in patients cated transplantation care.
with longer HD vintage.36 37 In our cohort, recipients with
HD had significantly longer pretransplant dialysis dura-
tion compared with the PD group, thereby consequently lImItAtIOns
conferring a greater risk of allograft failure after kidney This nationwide cohort study using the NHI database
transplantation. has some inherent limitations. First, while the NHI data-
Regarding the impact of the pretransplant dialysis base contains deidentified patient information encrypted
modality on kidney transplantation outcomes, the avail- with ICD codes, there are no available clinical donor or
able evidences derived from observational studies are recipient details such as living or deceased donor, graft
inconsistent and conflicting.38–42 Table 5 summarises condition, DGF, ischaemia time, panel reactive antibody
these previous studies and appraises their qualities with (PRA) level or sensitisation, renal function (such as
the Newcastle-Ottawa Scale for observational studies glomerular filtration rate), HLA mismatch, ABO incom-
as well as the Preferred Reporting Items for Systematic patibility, acute rejection and graft failure, etc. There-
Reviews and Meta-Analyses tool for systematic review.43 44 fore, we could not estimate the influences of these factors
These contradictory results may originate from different on post-transplant outcomes and make corresponding
study design, country, population, follow-up duration, adjustments. Second, the great differences in clinical
era and the statistic method used to address confounding and demographic features between HD and PD patients
factors. A recent review concluded that PD conferred a might strongly confound the outcomes and undermine
lower incidence of DGF and better 5-year patient survival, our comparisons. Even though we had excluded unsuit-
but not graft survival, and recommended PD as the able populations and adjusted significant pretransplant
better choice of pretransplant dialysis modality.13 Taken features in the propensity-adjusted log-binomial model
8 Lin H-T, et al. BMJ Open 2018;8:e020558. doi:10.1136/bmjopen-2017-020558
Open Access
Table 5 Review of studies evaluating impact of dialysis modality on kidney-transplant outcomes
Authors (year),*
country Study design Patient no Follow-up period Post-transplant outcomes Favour Quality†
Goldfarb-Rumyantzev Cohort, retrospective 92 844 patients from USRDS 10 years PD was associated with shorter PD Good
et al (2005),41 USA database database (during 1990–1999) time on dialysis, better graft and
patient survival
Molnar et al (2011),40 Cohort, retrospective 14 508 recipients 6 years PD with lower mortality rate, but PD Fair
USA database (HD:12416, PD:2092) (during 2001–2006) no differences in DGF or death-
censored graft survival after
adjustment
Schwenger et Cohort, multicentre 57 315 recipients (HD: 45 651, Median 5 years PD with lower all-cause mortality PD Good
al (2011),42 Germany PD: 11 664) (during 1998–2007) but similar graft survival
Kramer et al (2012),39 Cohort, retrospective 29 088 adult recipients from 16 Median 5 years PD was associated with better Non Good
the Netherlands database European renal registries (during 1999–2008) patient and graft survivals, but no
longer significant after instrumental
variable analysis
López-Oliva et al Cohort, 236 recipients (HD:118, Median 8.5 years PD has better long-term patient PD Fair
(2013),12 Spain retrospective single- PD:118) (during 1990–2002) survival, but not graft survival in
centre the multivariate analysis
Martins et al (2015),11 Cohort, retrospective 158 recipients of pancreas- Median 5.9 years PD with more intra-abdominal HD Fair
Portugal single centre kidney transplantation (during 2000–2013) infection, leading to pancreas loss
(HD:119, PD:39) and renal thrombosis, with adverse
impact on patient survival
Dipalma et al (2016),14 Cohort, retrospective 180 donor-matched recipients Median 73 months No significant difference in death- Non Good
Spain single centre (HD:80, PD:80) (during 1990–2007) censored graft survival and patient
survival after propensity-score
adjustment
Tang et al (2016),13 Meta-analysis 12 studies, excluded children, – PD conferred less DGF, better PD Fair
China sample <100 pts 5-year patient survival, but not
graft survival
*The references are listed in the order of published year.
†Quality assessments were based on the Newcastle-Ottawa Scale for observational cohort studies and the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses tool for systemic review/meta-analysis. All studies were rated as ‘good, fair or poor’ according to fulfilment of applied assessment checklist.
DGF, delayed graft function; HD, haemodialysis; PD, peritoneal dialysis; USRDS, United States Renal Data System.
and multivariate analyses, there might be other uniden- long follow-up duration compared with other studies,
tified covariates (ie, residual selection bias) that could making our results more convincing.
potentially confound the post-transplant outcomes.
Third, the true cause of death is inaccessible in our NHI
database, so we could not distinguish death with func-
COnClusIOns
tioning graft, death with graft failure or cardiovascular
In conclusion, our nationwide cohort study using the
death. Fourth, coding errors or miscoding might exist
NHI database of Taiwan showed that kidney-transplant
in the large nationwide database, even though the accu-
recipients with pretransplant chronic HD were associated
racy of our NHI database has been reported in previous
with more dialysis events during kidney transplantation,
studies.15 Finally, our study period spanned from 1998 to
and thereby a higher possibility of DGF. Besides, kidney
2011. During these years, the medical therapies for dial-
recipients with chronic HD had significantly higher risks
ysis patients and interventions for kidney-transplant recip-
of developing post-transplant de novo ischaemic heart
ients have changed substantially, so our results might be disease, tuberculosis and hepatitis C after propensity
confounded by this era effect. score adjustment; and had a higher risk of long-term
Despite these limitations, this study has several strengths. death-censored graft failure in the multivariate analysis
First, this is the first nationwide population-based cohort after adjustment.
study to demonstrate that pretransplant HD contrib-
uted to higher risks of post-transplant de novo diseases Acknowledgements This study was based on data from the NHI research
and allograft failure after kidney transplantation. The database provided by the Bureau of NHI, Department of Health and managed by the
National Health Research Institutes. The interpretations and conclusions contained
evidence-based comparison of pretransplant dialysis
herein do not represent the views of the Bureau of the NHI, Department of Health or
modality on post-transplant outcomes provides valuable National Health Research Institutes.
information for dialysis patients awaiting kidney trans-
Contributors All authors made contributions to the paper and authorised the
plantation, especially in Asian population. Second, we submission. H-TL, F-CL and H-PY contributed clinical interpretation of results
used a nationwide database that covers more than 99.6% and drafted the manuscript. H-TL and F-CL designed the study, supported data
analyses and interpretation and supported manuscript preparation. J-RL provided
of the Taiwanese population, and its representativeness
data management, analyses and data interpretation. S-TP contributed clinical
and integrity have been previously validated. Third, our
interpretation. All authors contributed to manuscript preparation and critical
study had a relatively large number of recipients and a revision.
Lin H-T, et al. BMJ Open 2018;8:e020558. doi:10.1136/bmjopen-2017-020558 9
Open Access
Funding This work was partially supported by grants from the National Science 17. Noordzij M, Leffondré K, van Stralen KJ, et al. When do we need
Council of Taiwan (project 103-2314-B-182A-070-MY2, 103-2314-B-182- competing risks methods for survival analysis in nephrology?
043-MY2, and 105-2314-B-182A-137-MY3) and the Chang Gung Memorial Nephrol Dial Transplant 2013;28:2670–7.
18. Deb S, Austin PC, Tu JV, et al. A review of propensity-score
Hospital (project CMRPG3F1011, CMRPG3D1671 and CORPG3E0131).
methods and their use in cardiovascular research. Can J Cardiol
Competing interests None declared. 2016;32:259–65.
19. Branch-Elliman W, Ripollone JE, O'Brien WJ, et al. Risk of surgical
Patient consent Not required. site infection, acute kidney injury, and Clostridium difficile infection
ethics approval The present study was evaluated and approved by the following antibiotic prophylaxis with vancomycin plus a beta-lactam
versus either drug alone: a national propensity-score-adjusted
Institutional Review Board of Chang Gung Medical Foundation, Taiwan (approval
retrospective cohort study. PLoS Med 2017;14:e1002340.
number: 104-6697B).
20. Ali MS, Groenwold RH, Belitser SV, et al. Reporting of covariate
Provenance and peer review Not commissioned; externally peer reviewed. selection and balance assessment in propensity score analysis is
suboptimal: a systematic review. J Clin Epidemiol 2015;68:122–31.
Data sharing statement No additional data are available. 21. Lin YC, Lin YC, Kao CC, et al. Health policies on dialysis modality
Open Access This is an Open Access article distributed in accordance with the selection: a nationwide population cohort study. BMJ Open
2017;7:e013007.
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
22. Hwang SJ, Tsai JC, Chen HC. Epidemiology, impact and preventive
permits others to distribute, remix, adapt, build upon this work non-commercially,
care of chronic kidney disease in Taiwan. Nephrology 2010;15(Suppl
and license their derivative works on different terms, provided the original work is 2):3–9.
properly cited and the use is non-commercial. See: http:// creativecommons. org/ 23. Fuquay R, Teitelbaum I. Transplant outcomes and dialysis modality.
licenses/ by- nc/ 4. 0/ Contrib Nephrol 2012;178:251–7.
24. Tsai TC, Chen YC, Lo CW, et al. Incidence and renal survival of
© Article author(s) (or their employer(s) unless otherwise stated in the text of the
ESRD in the young Taiwanese population. Clin J Am Soc Nephrol
article) 2018. All rights reserved. No commercial use is permitted unless otherwise 2014;9:302–9.
expressly granted. 25. D'Marco L, Bellasi A, Mazzaferro S, et al. Vascular calcification,
bone and mineral metabolism after kidney transplantation. World J
Transplant 2015;5:222–30.
26. Eleftheriadis T, Antoniadi G, Liakopoulos V, et al. Disturbances
of acquired immunity in hemodialysis patients. Semin Dial
2007;20:440–51.
reFerenCes 27. Nashan B, Abbud-Filho M, Citterio F. Prediction, prevention, and
1. Goldfarb-Rumyantzev A, Hurdle JF, Scandling J, et al. Duration of management of delayed graft function: where are we now? Clin
end-stage renal disease and kidney transplant outcome. Nephrol Dial Transplant 2016;30:1198–208.
Transplant 2005;20:167–75. 28. Schröppel B, Legendre C. Delayed kidney graft function: from
2. Amaral S, Sayed BA, Kutner N, et al. Preemptive kidney mechanism to translation. Kidney Int 2014;86:251–8.
transplantation is associated with survival benefits among pediatric 29. Fontana I, Santori G, Ginevri F, et al. Impact of pretransplant dialysis
patients with end-stage renal disease. Kidney Int 2016;90:1100–8. on early graft function in pediatric kidney recipients. Transpl Int
3. Saran R, Robinson B, Abbott KC, et al. US Renal data system 2016 2005;18:785–93.
annual data report: epidemiology of kidney disease in the United 30. Lobbedez T, Lecouf A, Abbadie O, et al. Peritoneal dialysis and renal
States. Am J Kidney Dis 2017;69(Suppl 1):A7–8. transplantation. Contrib Nephrol 2009;163:250–6.
4. Klarenbach SW, Tonelli M, Chui B, et al. Economic evaluation of 31. Stoumpos S, Jardine AG, Mark PB. Cardiovascular morbidity and
dialysis therapies. Nat Rev Nephrol 2014;10:644–52. mortality after kidney transplantation. Transpl Int 2015;28:10–21.
5. Kwong VW-K, Li PK-T. Peritoneal dialysis in Asia. Kidney Dis 32. Chen CH, Wu MJ, Lin CH, et al. Comparison of tuberculosis infection
2015;1:147–56. rates in a national database of renal transplant patients with data
6. Chang YT, Hwang JS, Hung SY, et al. Cost-effectiveness of from a single center in Taiwan. Transplant Proc 2014;46:588–91.
hemodialysis and peritoneal dialysis: a national cohort study with 14 33. Tsai HI, Yu HP, Hp Y. A review of nationwide population study
years follow-up and matched for comorbidities and propensity score. of organ transplantation in Taiwan. Acta Anaesthesiol Taiwan
Sci Rep 2016;6:30266. 2016;54:70–4.
7. Mehrotra R, Devuyst O, Davies SJ, et al. The current state of 34. Lee PC, Chiang YJ, Chen ST. Deceased donor kidney transplantation
peritoneal dialysis. J Am Soc Nephrol 2016;27:3238–52. in Taiwan in 2015. Clin Transpl 2014:55–9.
8. Legendre C, Canaud G, Martinez F. Factors influencing long-term 35. Augustine JJ, Poggio ED, Clemente M, et al. Hemodialysis vintage,
outcome after kidney transplantation. Transpl Int 2014;27:19–27. black ethnicity, and pretransplantation antidonor cellular immunity in
9. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific kidney transplant recipients. J Am Soc Nephrol 2007;18:1602–6.
causes of kidney allograft loss. Am J Transplant 2009;9:527–35. 36. Helanterä I, Salmela K, Kyllönen L, et al. Pretransplant dialysis
10. Wu DA, Robb ML, Watson CJE, et al. Barriers to living donor kidney duration and risk of death after kidney transplantation in the current
transplantation in the United Kingdom: a national observational era. Transplantation 2014;98:458–64.
study. Nephrol Dial Transplant 2017;32:890–900. 37. Chen PD, Tsai MK, Lee CY, et al. Gender differences in renal
11. Martins LS, Malheiro J, Pedroso S, et al. Pancreas-kidney transplant graft survival. J Formos Med Assoc 2013;112:783–8.
transplantation: impact of dialysis modality on the outcome. Transpl 38. Couchoud C, Bolignano D, Nistor I, et al. Dialysis modality choice in
Int 2015;28:972–9. diabetic patients with end-stage kidney disease: a systematic review
12. López-Oliva MO, Rivas B, Pérez-Fernández E, et al. Pretransplant of the available evidence. Nephrol Dial Transplant 2015;30:310–20.
peritoneal dialysis relative to hemodialysis improves long-term 39. Kramer A, Jager KJ, Fogarty DG, et al. Association between pre-
survival of kidney transplant patients: a single-center observational transplant dialysis modality and patient and graft survival after kidney
study. Int Urol Nephrol 2014;46:825–32. transplantation. Nephrol Dial Transplant 2012;27:4473–80.
13. Tang M, Li T, Liu H. A comparison of transplant outcomes in 40. Molnar MZ, Mehrotra R, Duong U, et al. Dialysis modality and
peritoneal and hemodialysis patients: a meta-analysis. Blood Purif outcomes in kidney transplant recipients. Clin J Am Soc Nephrol
2016;42:170–6. 2012;7:332–41.
14. Dipalma T, Fernández-Ruiz M, Praga M, et al. Pre-transplant dialysis 41. Goldfarb-Rumyantzev AS, Hurdle JF, Scandling JD, et al. The role
modality does not influence short- or long-term outcome in kidney of pretransplantation renal replacement therapy modality in kidney
transplant recipients: analysis of paired kidneys from the same allograft and recipient survival. Am J Kidney Dis 2005;46:537–49.
deceased donor. Clin Transplant 2016;30:1097–107. 42. Schwenger V, Döhler B, Morath C, et al. The role of pretransplant
15. Sung SF, Hsieh CY, Lin HJ, et al. Validation of algorithms to identify dialysis modality on renal allograft outcome. Nephrol Dial Transplant
stroke risk factors in patients with acute ischemic stroke, transient 2011;26:3761–6.
ischemic attack, or intracerebral hemorrhage in an administrative 43. Wells G, Shea B, O’ Connell D, et al. The Newcastle-Ottawa scale
claims database. Int J Cardiol 2016;215:277–82. (NOS) for assessing the quality of nonrandomised studies in meta-
16. Rigoni M, Torri E, Nollo G, et al. Survival and time-to-transplantation analyses. Ottawa, ON: Ottawa Hospital Research Institute.
of peritoneal dialysis versus hemodialysis for end-stage renal disease 44. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for
patients: competing-risks regression model in a single Italian center systematic reviews and meta-analyses: the PRISMA statement. PLoS
experience. J Nephrol 2017;30:441–7. Med 2009;6:e1000097.
10 Lin H-T, et al. BMJ Open 2018;8:e020558. doi:10.1136/bmjopen-2017-020558
